Abstract:
The review explores the potential applications of nanotechnologies and biomedical engineering approaches in the diagnosis and treatment of Dupuytren disease. Several studies have investigated the use of various types of nanoparticles for drug delivery, including paclitaxel, mitomycin C, and verapamil, which have shown promising results in reducing fibrosis and contracture formation in in vitro and animal models. Additionally, the use of tissue-engineered constructs, such as cell-seeded collagen matrices and nanofibrous scaffolds, incorporating platelet-rich plasma, has also shown potential in improving hand function and reducing nodule size in Dupuytren disease patients.